Eton Pharmaceuticals Celebrates FDA Approval of KHINDIVI™
In a significant milestone for pediatric healthcare, Eton Pharmaceuticals, Inc. has achieved U.S. FDA approval for KHINDIVI™ (hydrocortisone) Oral Solution. This formulation is remarkable as it represents the first and only FDA-approved liquid form of hydrocortisone designed to treat adrenocortical insufficiency in children aged five and older.
Overview of KHINDIVI and Its Benefits
KHINDIVI distinguishes itself by offering a 1mg/ml strength that negates the necessity for splitting or crushing tablets, thereby simplifying the dosing process. This ready-to-use oral solution eliminates the hassle of refrigeration or complex preparation, making it an exceptional choice for families dealing with the challenges of administering medication to children. The ease of use makes it particularly valuable for patients who struggle with swallowing tablets or those needing specific administration methods, such as through a gastric tube.
Impact of FDA Approval
Sean Brynjelsen, CEO of Eton Pharmaceuticals, expressed his excitement about the approval, noting that it marks a crucial advancement for pediatric patients facing adrenal insufficiency. The approval reflects the hard work and dedication of Eton's team in navigating the complex development, clinical, and regulatory landscape.
Commitment to Patients and Healthcare Providers
Eton's commercial team is fully prepared to launch KHINDIVI shortly after the approval. There is a strong commitment to educate pediatric endocrinologists nationwide about this new treatment option. Eton recognizes the need for precise and consistent hydrocortisone dosing, allowing healthcare providers the ability to titrate doses to meet the unique needs of each child.
Clinical Insights and Community Support
Dr. Kyriakie Sarafoglou, a prominent figure in pediatric endocrinology at the University of Minnesota, highlighted the importance of accurate dosing in managing adrenal insufficiency. Having an FDA-approved liquid formulation provides physicians with a new tool to enhance clinical outcomes during critical growth periods in children's lives.
Advocacy from the Community
Dina Matos, Executive Director of the CARES Foundation, applauded the introduction of KHINDIVI, emphasizing its significance in offering a much-needed solution to families navigating the challenges of congenital adrenal hyperplasia (CAH). The availability of accurately dosed treatments like KHINDIVI is crucial for optimizing care and reducing the burden on parents and caregivers.
Market Introduction and Support Programs
KHINDIVI is set to be available soon in the United States and will be provided exclusively through Anovo, a specialty pharmacy that supports patients with rare conditions. Anovo will manage the Eton Cares Program, which includes prescription fulfillment, insurance benefit investigations, patient support, and financial assistance for qualifying families. Through this initiative, Eton aims to alleviate the cost barrier, allowing for zero co-pays for eligible patients.
How Healthcare Providers Can Prescribe KHINDIVI
Healthcare providers looking to prescribe KHINDIVI can do so easily by e-prescribing to Anovo or submitting a patient referral form. This straightforward process helps ensure that patients get the treatment they need without unnecessary delays, marking a new chapter in the management of pediatric adrenal insufficiency.
Understanding Adrenocortical Insufficiency
Adrenocortical insufficiency is a serious condition that affects hormone production in the adrenal glands. Eton estimates there are over 5,000 patients aged between 5 and 17 in the U.S. suffering from this condition. The company anticipates that the combined peak sales of KHINDIVI and its other product ALKINDI SPRINKLE® could exceed $50 million annually, highlighting the significant market need.
Key Features of KHINDIVI
KHINDIVI aims to meet the specific dosing needs of pediatric patients. With its convenient formulation, it allows for tailored dosing that can be adjusted to each child's development and health status, promoting better monitoring and overall health outcomes.
Adverse Reactions and Patient Safety
With any medication, understanding potential adverse reactions is critical. KHINDIVI is generally well-tolerated; however, healthcare providers must be vigilant about symptoms of adrenal crises or reactions due to inactive ingredients, including hyperosmolarity. As patients transition to this new oral solution, effective monitoring and communication are vital to ensuring safety and efficacy.
Final Notes on the Launch
Eton Pharmaceuticals is dedicated to providing treatments that improve the lives of those with rare diseases. The launch of KHINDIVI emphasizes their commitment to innovation and patient-centric solutions in the pharmaceutical landscape.
Frequently Asked Questions
What is KHINDIVI used for?
KHINDIVI is indicated as replacement therapy for pediatric patients aged 5 years and older with adrenocortical insufficiency.
How does KHINDIVI differ from other hydrocortisone formulations?
KHINDIVI is a ready-to-use oral liquid solution that does not require mixing or refrigeration, making it easier for patients and caregivers to administer.
Where can KHINDIVI be obtained?
KHINDIVI will be available exclusively through Anovo, a specialty pharmacy that specializes in serving patients with rare conditions.
Are there any special precautions with KHINDIVI?
Patients should be monitored for potential adverse reactions, including adrenal crises. It's vital to communicate with healthcare providers about any symptoms experienced during treatment.
What support programs are offered with KHINDIVI?
The Eton Cares Program provides financial assistance, insurance verification, and educational support to help families access KHINDIVI without excessive financial burdens.
